Comparative Pharmacology
Head-to-head clinical analysis: CYMBALTA versus KHEDEZLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYMBALTA versus KHEDEZLA.
CYMBALTA vs KHEDEZLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that selectively inhibits the reuptake of serotonin and norepinephrine, thereby enhancing neurotransmission in the central nervous system.
60 mg orally once daily, without regard to meals; some patients may benefit from a starting dose of 30 mg once daily for 1 week before increasing to 60 mg once daily.
20 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8–17 hours); supports once-daily dosing with consistent drug levels.
Approximately 11 hours; supports once-daily dosing; steady state reached within 3 days.
Renal: approximately 70% as metabolites (duloxetine glucuronide conjugates and sulfate conjugates), 20% as unchanged drug in urine; fecal: approximately 20% as metabolites; biliary: minor contribution.
Primarily renal (70-80% as unchanged desvenlafaxine), with minor fecal elimination (approx. 5%).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant